Targeting of NMDA receptors in new treatments for schizophrenia.
about
Early interventions in risk groups for schizophrenia: what are we waiting for?Brexpiprazole: so far so goodConsensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics.Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode PsychosisInvolvement of the glutamate/glutamine cycle and glutamate transporter GLT-1 in antidepressant-like effects of Xiao Yao san on chronically stressed miceThe Emerging Role for Zinc in Depression and Psychosis.Dietary Intake of Sulforaphane-Rich Broccoli Sprout Extracts during Juvenile and Adolescence Can Prevent Phencyclidine-Induced Cognitive Deficits at AdulthoodDifferential Effects of D-Cycloserine and ACBC at NMDA Receptors in the Rat Entorhinal Cortex Are Related to Efficacy at the Co-Agonist Binding Site.Neuropsychological Impairment and Its Association with Violence Risk in Japanese Forensic Psychiatric Patients: A Case-Control StudyEndogenous 24S-hydroxycholesterol modulates NMDAR-mediated function in hippocampal slices.Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorderSearching for cognitive enhancement in the Morris water maze: better and worse performance in D-amino acid oxidase knockout (Dao(-/-)) mice.Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study.Cycloid psychoses in the psychosis spectrum: evidence for biochemical differences with schizophreniaTargeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerBrain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic TargetsPrediction of N-Methyl-D-Aspartate Receptor GluN1-Ligand Binding Affinity by a Novel SVM-Pose/SVM-Score Combinatorial Ensemble Docking SchemeEffects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial.Investigational drugs for anxiety in patients with schizophrenia.Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.The recency ratio is associated with reduced CSF glutamate in late-life depression.Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation.The effect of add-on memantine on global function and quality of life in schizophrenia: A randomized, double-blind, controlled, clinical trial.Familial Influences on Mismatch Negativity and Its Association with Plasma Glutamate Level: A Magnetoencephalographic Study in Twins.Glutamatergic system abnormalities in posttraumatic stress disorder.Taurine and Epidermal Growth Factor Belong to the Signature of First-Episode Psychosis.Early Intervention for Psychosis with N-Methyl-D-Aspartate Receptor Modulators.Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding.Dietary glucoraphanin prevents the onset of psychosis in the adult offspring after maternal immune activation.Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression.Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine.Serine enantiomers as diagnostic biomarkers for schizophrenia and bipolar disorder.Intake of 7,8-dihydroxyflavone from pregnancy to weaning prevents cognitive deficits in adult offspring after maternal immune activation.CSF GABA is reduced in first-episode psychosis and associates to symptom severity.Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine.Increased serum levels of serine enantiomers in patients with depression.Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine.Clozapine influences cytoskeleton structure and calcium homeostasis in rat cerebral cortex and has a different proteomic profile than risperidone.
P2860
Q26747545-F75C4E07-CC05-489E-8CC6-C37755B1644BQ26766401-3290B15D-45B0-49B6-866D-FEF493F18D38Q31108616-B53DCC9C-A4B3-466D-B0DB-356B2034CE5EQ33720060-8A538972-219C-4558-B33C-6D26BB0E702DQ33814381-66657A36-81AE-4B4F-9969-6F1F6333EF0AQ33857369-FA561C98-5040-48F6-ACA2-E7F99E2885B8Q35673126-8286E4D5-1ABB-41DB-A4D5-21C25E848423Q35699606-47F85577-8FA6-4D87-BB5E-5F535F0259A3Q35908405-803F3431-8E2B-4F64-B84C-66C66A2919B4Q36729728-E6CEBDBA-5264-4807-B9DC-4F9ABB8BE65BQ36799359-94FB23EA-826F-40F5-A9AA-83326A029E25Q36866353-75B7D42F-75D0-4C67-B9FB-85F86110397CQ36915565-7EC0938E-EA31-496C-B1F4-BFDBDEB59712Q37158915-670BE08B-1A4C-4A27-95A2-EC6E01BA6131Q37258840-435F00B5-098C-44F9-A077-9F8E1611E069Q37310546-4E4A37C6-1AD9-4DE2-A623-D2E04FCF7ADDQ37563518-50A4B1E5-AD59-4EF5-8AD2-B537D0874B1EQ37662441-AC61C2E2-FA7B-497A-843A-02E6D7F950B6Q37740962-CEEBD2F4-A8B8-4BBA-A770-CDFEDCD2E981Q38271298-904EC8F0-1BF2-4BDA-9934-7823FA12AC4BQ38661176-037B4C79-007E-4ED4-AE31-87E4098AB9A3Q38890806-76BCC70A-8F26-4DC4-A362-45BE92ECC0EEQ39308929-237875AE-3D79-40DC-8723-77BDD0647B5EQ40448883-44B16585-A368-484E-8FBE-C75AF4642808Q41098334-0DB687C3-8A02-46C6-A2FA-C922F8AE6A7BQ41653821-E599CA49-E953-4BAF-BF6A-B02869F12C4CQ41952721-7C0CD691-9842-49BF-9F4C-879E790DD190Q42419288-A5A21B38-2D0B-4A48-B248-58EEC89BE41CQ43152351-B6513F3A-8497-4F5F-B8A4-DB8A4974F91DQ47401011-C8187485-B5C5-45BD-B6EB-C43686C19E0BQ47549654-8DA55E8B-FCCE-445A-8DDE-67C59F145837Q47633542-9F985DEA-CDE4-46C8-B377-35DBB89400DAQ47660018-A631233F-FD05-4D7D-A4E5-D96D388BAA1AQ47706465-3ADD3050-9112-4B19-8A6F-5941F1CE5481Q47746288-44DBF7C9-845C-42F0-A1A7-0E8B8F812B30Q47777392-F596AAC0-F446-44A9-B38B-226F94E7CCEDQ47820012-4955846A-2EDB-4169-8BD9-3A5C375C9332Q48071667-22C229C6-A18B-499E-A75A-98B67D20120AQ48345910-47B39CB8-EFAF-4D86-9D6A-049B2987C623Q48423771-F7C76C44-8E7A-4B06-8504-ADD02E1D94E5
P2860
Targeting of NMDA receptors in new treatments for schizophrenia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting of NMDA receptors in new treatments for schizophrenia.
@en
type
label
Targeting of NMDA receptors in new treatments for schizophrenia.
@en
prefLabel
Targeting of NMDA receptors in new treatments for schizophrenia.
@en
P2860
P1476
Targeting of NMDA receptors in new treatments for schizophrenia.
@en
P2093
Kenji Hashimoto
P2860
P304
P356
10.1517/14728222.2014.934225
P407
P50
P577
2014-06-26T00:00:00Z